In Vivo Studies of the Drug Carrying Magnetic Nanocomposite Spheres via Fluorescent Molecules

2010 ◽  
Author(s):  
H. E. Misak ◽  
R. Asmatulu ◽  
J. S. Gopu ◽  
S. Zheng ◽  
P. Wooley ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Targeted Drug Delivery ◽  
Drug Carrier ◽  
Fluorescent Microscopy ◽  
In Vivo Studies ◽  
Fluorescent Nanoparticles ◽  
In Vivo Test ◽  
Straightforward Method ◽  
Targeted Drug

Nanospheres utilized in targeted drug delivery systems have seen much attention, however it is difficult to detect the nanospheres in an in-vivo test due to their nanoscale in size. This is a crucial step in targeted drug delivery to show the nanosphere being concentrated at the spot of interest. Nanospheres developed by oil in oil (o/o) emulsion technique have the advantage of encapsulating molecules, such as 1,6-Diphenyl-1,3,5-hexatriene (DPH), without damages and chemical alterations. In current study, DPH was encapsulated into a nanosphere as a fluorescing tracer to visualize the nanospheres trafficking in a mouse model of squamous cell carcinoma (SCC). The SCC tumors were established on nude mice. 0.5 ml of a 0.3 mg/ml solution of fluorcescent nanospheres were subcutaneously injected around the tumor. The injections of the drug carrier system were repeated at 2-day intervals till the sacrifice of the tumor-bearing animals on day 10. The tumors were retrieved for frozen and paraffin-embedded histological preparation. Fluorsescent microscopy was used to image the frozen sections, and compared with H&E stained sections. The fluorescence nanoparticles were easily identifiable under fluorescent microscopy, while typical histology images were unable to detect the nanospheres. The data suggest that fluorescent nanoparticles can be used to identify the location or localization of the nanospheres in an in-vivo environment in a simple and straightforward method that aids in characterization of targeted drug delivery.

scholarly journals Pharmacokinetic—Pharmacodynamic Modeling of Tumor Targeted Drug Delivery Using Nano-Engineered Mesenchymal Stem Cells

Pharmaceutics ◽  
2021 ◽  
Vol 13 (1) ◽  
pp. 92
Author(s):  
Shen Cheng ◽  
Susheel Kumar Nethi ◽  
Mahmoud Al-Kofahi ◽  
Swayam Prabha
Keyword(s):  
Drug Delivery ◽  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Targeted Drug Delivery ◽  
Quantitative Description ◽  
In Vivo Studies ◽  
Pharmacodynamic Modeling ◽  
Targeted Drug

Nano-engineered mesenchymal stem cells (nano-MSCs) are promising targeted drug delivery platforms for treating solid tumors. MSCs engineered with paclitaxel (PTX) loaded poly(lactide-co-glycolide) (PLGA) nanoparticles (NPs) are efficacious in treating lung and ovarian tumors in mouse models. The quantitative description of pharmacokinetics (PK) and pharmacodynamics (PD) of nano-MSCs is crucial for optimizing their therapeutic efficacy and clinical translatability. However, successful translation of nano-MSCs is challenging due to their complex composition and physiological mechanisms regulating their pharmacokinetic-pharmacodynamic relationship (PK–PD). Therefore, in this study, a mechanism-based preclinical PK–PD model was developed to characterize the PK–PD relationship of nano-MSCs in orthotopic A549 human lung tumors in SCID Beige mice. The developed model leveraged literature information on diffusivity and permeability of PTX and PLGA NPs, PTX release from PLGA NPs, exocytosis of NPs from MSCs as well as PK and PD profiles of nano-MSCs from previous in vitro and in vivo studies. The developed PK–PD model closely captured the reported tumor growth in animals receiving no treatment, PTX solution, PTX-PLGA NPs and nano-MSCs. Model simulations suggest that increasing the dosage of nano-MSCs and/or reducing the rate of PTX-PLGA NPs exocytosis from MSCs could result in improved anti-tumor efficacy in preclinical settings.

scholarly journals Chitosan overlaid Fe3O4/rGO nanocomposite for targeted drug delivery, imaging, and biomedical applications

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Viswanathan Karthika ◽  
Mohamad S. AlSalhi ◽  
Sandhanasamy Devanesan ◽  
Kasi Gopinath ◽  
Ayyakannu Arumugam ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Folic Acid ◽  
Targeted Drug Delivery ◽  
Drug Carrier ◽  
Drug Loading ◽  
Antioxidant Properties ◽  
Targeted Drug ◽  
Loading Amount

Abstract A hybrid and straightforward nanosystem that can be used simultaneously for cancer-targeted fluorescence imaging and targeted drug delivery in vitro was reported in this study. A chitosan (CS) polymer coated with reduced graphene oxide (rGO) and implanted with Fe3O4 nanoparticles was fabricated. The fundamental physicochemical properties were confirmed via FT-IR, XRD, FE-SEM, HR-TEM, XPS, and VSM analysis. The in vivo toxicity study in zebrafish showed that the nanocomposite was not toxic. The in vitro drug loading amount was 0.448 mg/mL−1 for doxorubicin, an anticancer therapeutic, in the rGO/Fe3O4/CS nanocomposite. Furthermore, the pH-regulated release was observed using folic acid. Cellular uptake and multimodal imaging revealed the benefit of the folic acid-conjugated nanocomposite as a drug carrier, which remarkably improves the doxorubicin accumulation inside the cancer cells over-express folate receptors. The rGO/Fe3O4/CS nanocomposite showed enhanced antibiofilm and antioxidant properties compared to other materials. This study's outcomes support the use of the nanocomposite in targeted chemotherapy and the potential applications in the polymer, cosmetic, biomedical, and food industries.

Transferrin Modified Graphene Oxide for Glioma-Targeted Drug Delivery: In Vitro and in Vivo Evaluations

2013 ◽  
Vol 5 (15) ◽  
pp. 6909-6914 ◽  
Author(s):  
Guodong Liu ◽  
He Shen ◽  
Jinning Mao ◽  
Liming Zhang ◽  
Zhen Jiang ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Graphene Oxide ◽  
Targeted Drug Delivery ◽  
Modified Graphene Oxide ◽  
Targeted Drug ◽  
Modified Graphene

scholarly journals Erythrocytes as Carriers: From Drug Delivery to Biosensors

Pharmaceutics ◽  
2020 ◽  
Vol 12 (3) ◽  
pp. 276 ◽  
Author(s):  
Larisa Koleva ◽  
Elizaveta Bovt ◽  
Fazoil Ataullakhanov ◽  
Elena Sinauridze
Keyword(s):  
Drug Delivery ◽  
Targeted Drug Delivery ◽  
Reticuloendothelial System ◽  
In Vivo Studies ◽  
Bioactive Substances ◽  
Target Organs ◽  
Wide Range ◽  
Opening Up ◽  
Gradual Release

Drug delivery using natural biological carriers, especially erythrocytes, is a rapidly developing field. Such erythrocytes can act as carriers that prolong the drug’s action due to its gradual release from the carrier; as bioreactors with encapsulated enzymes performing the necessary reactions, while remaining inaccessible to the immune system and plasma proteases; or as a tool for targeted drug delivery to target organs, primarily to cells of the reticuloendothelial system, liver and spleen. To date, erythrocytes have been studied as carriers for a wide range of drugs, such as enzymes, antibiotics, anti-inflammatory, antiviral drugs, etc., and for diagnostic purposes (e.g., magnetic resonance imaging). The review focuses only on drugs loaded inside erythrocytes, defines the main lines of research for erythrocytes with bioactive substances, as well as the advantages and limitations of their application. Particular attention is paid to in vivo studies, opening-up the potential for the clinical use of drugs encapsulated into erythrocytes.

Sign in / Sign up

Export Citation Format

Share Document